Compare Logitech International SA (LOGI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Regeneron Pharmaceuticals Inc — how do they compare? Logitech International SA trades at $103.84 (market cap $14.65B), while Regeneron Pharmaceuticals Inc trades at $672.4 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.8× Logitech International SA's market cap, and Logitech International SA pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| LOGI | REGN | |
|---|---|---|
Market Cap | $14.65B | $70.47B |
Sector | Technology | Health |
52-Week High | $126.69 | $812.27 |
52-Week Low | $85.84 | $545.46 |
Enterprise Value | $13.00B | $64.42B |
Dividend Yield | 1.67% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
